Chardan Capital Reiterates “Buy” Rating for Ocugen (NASDAQ:OCGN)

Ocugen (NASDAQ:OCGN)‘s stock had its “buy” rating reaffirmed by Chardan Capital in a research report issued on Thursday,Benzinga reports. They currently have a $7.00 price target on the stock. Chardan Capital’s target price points to a potential upside of 260.84% from the stock’s previous close.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Ocugen in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Ocugen currently has a consensus rating of “Hold” and a consensus target price of $7.00.

Ocugen Trading Down 1.0%

Shares of Ocugen stock opened at $1.94 on Thursday. The company has a quick ratio of 1.85, a current ratio of 1.85 and a debt-to-equity ratio of 8.04. Ocugen has a 12-month low of $0.52 and a 12-month high of $2.00. The company has a market capitalization of $605.87 million, a price-to-earnings ratio of -8.82 and a beta of 2.75. The firm’s 50-day moving average price is $1.57 and its two-hundred day moving average price is $1.42.

Ocugen (NASDAQ:OCGN) last issued its earnings results on Wednesday, March 4th. The company reported ($0.06) EPS for the quarter, meeting the consensus estimate of ($0.06). The company had revenue of ($0.19) million during the quarter, compared to analysts’ expectations of $0.86 million. Ocugen had a negative net margin of 1,192.18% and a negative return on equity of 491.22%. On average, analysts forecast that Ocugen will post -0.2 earnings per share for the current fiscal year.

Institutional Trading of Ocugen

Hedge funds and other institutional investors have recently modified their holdings of the stock. UBS Group AG increased its holdings in shares of Ocugen by 373.2% during the fourth quarter. UBS Group AG now owns 4,849,353 shares of the company’s stock worth $6,547,000 after buying an additional 3,824,474 shares in the last quarter. State Street Corp grew its position in Ocugen by 193.6% during the 4th quarter. State Street Corp now owns 3,978,738 shares of the company’s stock worth $5,371,000 after acquiring an additional 2,623,361 shares during the last quarter. Marshall Wace LLP acquired a new position in Ocugen in the 4th quarter worth about $3,417,000. Goldman Sachs Group Inc. increased its holdings in Ocugen by 2,256.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,302,475 shares of the company’s stock worth $3,108,000 after purchasing an additional 2,204,765 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in Ocugen by 485.9% in the fourth quarter. Renaissance Technologies LLC now owns 1,700,400 shares of the company’s stock valued at $2,296,000 after purchasing an additional 1,410,200 shares during the last quarter. Institutional investors own 10.27% of the company’s stock.

Key Ocugen News

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: Completed enrollment in the OCU400 Phase 3 liMeliGhT registrational trial, with topline Phase 3 data expected in Q1 2027 — a clear regulatory milestone that advances OCU400 toward potential approval in 2027. Read More.
• Positive Sentiment: Management outlined a plan for a 2026 BLA submission and said it expects three pivotal filings within three years, alongside leadership expansion — signaling an accelerated regulatory and clinical push that could materially re-rate the equity if filings and readouts succeed. Read More.
• Positive Sentiment: Market/media reaction included headlines of “gains on results,” reflecting investor enthusiasm around recent clinical progress and messaging from management. This positive sentiment is likely why the shares received upward pressure earlier in the session. Read More.
• Neutral Sentiment: Management hosted the Q4 2025 earnings call and provided operational detail and Q&A; the call reiterated pipeline timelines (including OCU400) and discussed financial runway but added limited new near-term revenue catalysts. Read More.
• Negative Sentiment: Q4 financials disappointed on revenue and showed continued losses — reported EPS of ($0.06) matched estimates, but revenue missed expectations (reported near zero/negative revenue vs. analyst estimates) and net margin/ROE remain deeply negative, highlighting ongoing cash burn and execution risk. Read More.
• Negative Sentiment: Coverage outlets flagged the revenue shortfall and persistent quarterly loss, underscoring that until clinical milestones convert to approvals or partnerships, valuation hinges on successful trial outcomes and funding prospects. Read More.

Ocugen Company Profile

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.